These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18422634)

  • 21. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
    Strowig SM; Raskin P
    Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The effects of thiazolidinedione from the cardiologic viewpoint].
    Ziegler R
    Med Monatsschr Pharm; 2005 Oct; 28(10):365. PubMed ID: 16245456
    [No Abstract]   [Full Text] [Related]  

  • 23. Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.
    Pfützner A; Weber MM; Forst T
    Expert Opin Pharmacother; 2007 Aug; 8(12):1985-98. PubMed ID: 17696799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
    Simó R; Rodriguez A; Caveda E
    Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rosiglitazone: potential beneficial impact on cardiovascular disease.
    Viberti GC
    Int J Clin Pract; 2003 Mar; 57(2):128-34. PubMed ID: 12661797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pioglitazone. Review of its metabolic and systemic effects].
    Rodríguez Bernardino A; Cebrián Blanco S; Durán García S
    Rev Clin Esp; 2005 Dec; 205(12):610-20. PubMed ID: 16527183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.
    Bailey CJ
    Diabetes Obes Metab; 2005 Nov; 7(6):675-91. PubMed ID: 16219011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus.
    Irons BK; Greene RS; Mazzolini TA; Edwards KL; Sleeper RB
    Pharmacotherapy; 2006 Feb; 26(2):168-81. PubMed ID: 16466323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety of rosiglitazone in the treatment of type 2 diabetes.
    Singh S; Loke YK
    Expert Opin Drug Saf; 2008 Sep; 7(5):579-85. PubMed ID: 18759710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Glitazones critically evaluated].
    Schernthaner G
    Dtsch Med Wochenschr; 2007 Dec; 132(49):2619. PubMed ID: 18050024
    [No Abstract]   [Full Text] [Related]  

  • 31. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.
    Lebovitz HE
    Am J Cardiol; 2002 Sep; 90(5A):34G-41G. PubMed ID: 12231077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular risk and TZD: safe therapy for the elderly?
    Burt R; Townsend S; Armor B
    Consult Pharm; 2009 May; 24(5):392-4. PubMed ID: 19555148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
    Florkowski CM
    Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The current role of thiazolidinediones in diabetes management.
    Rizos CV; Kei A; Elisaf MS
    Arch Toxicol; 2016 Aug; 90(8):1861-81. PubMed ID: 27165418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early combination therapy with a thiazolidinedione for the treatment of type 2 diabetes.
    Kanzer-Lewis G
    Diabetes Educ; 2003; 29(6):954-8, 961. PubMed ID: 14692369
    [No Abstract]   [Full Text] [Related]  

  • 38. Thiazolidinediones: the Forgotten Diabetes Medications.
    Lebovitz HE
    Curr Diab Rep; 2019 Nov; 19(12):151. PubMed ID: 31776781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Metabolic and hemodynamic effects of combined treatment with metformine and rosiglitasone (avandium) in patients with diabetes mellitus type 2 and high cardiovascular risk].
    Demidova TIu; Erokhina EN
    Ter Arkh; 2007; 79(10):39-45. PubMed ID: 18154144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The "glitazones": rosiglitazone and pioglitazone.
    Papoushek C
    J Obstet Gynaecol Can; 2003 Oct; 25(10):853-7. PubMed ID: 14532954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.